Product Information Sheet for NR-56243

Human Respiratory Syncytial Virus, B1

Catalog No. NR-56243

For research use only. Not for use in humans.

Contributor:
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:
BEI Resources

Product Description:
Virus Classification: *Human Orthopneumovirus*, *Human respiratory syncytial virus*
Species: Human respiratory syncytial virus B
Strain/Isolate: B1
Original Source: Human respiratory syncytial virus (RSV), B1 was developed by multiple passages in Vero cells from an original human isolate in 1985, in West Virginia, USA.[1,2]

Material Provided:
Each vial contains approximately 1.0 mL of cell lysate and supernatant from *Cercopithecus aethiops* kidney cells (Vero) infected with RSV, B1.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:
NR-56243 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:
Host: *Cercopithecus aethiops* kidney cells (Vero; ATCC® CCL-81™)
Growth Medium: Eagle's Minimum Essential Medium containing Earle's Balanced Salt Solution (ATCC® 30-2003™), supplemented with 2% fetal bovine serum (ATCC® 30-2020™), or equivalent
Infection: Cells should be 80% to 90% confluent
Incubation: 5 to 7 days at 37°C and 5% CO_2
Cytopathic Effect: Syncytia formation and cell disruption

Citation:
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Human Respiratory Syncytial Virus, B1, NR-56243."

Biosafety Level: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:
1. Karron, R. A., et al. "Respiratory Syncytial Virus (RSV) SH and G Proteins Are Not Essential for Viral Replication *in vitro*: Clinical Evaluation and Molecular Characterization of a Cold-Passaged, Attenuated RSV Subgroup B Mutant." Proc. Natl. Acad. Sci. U.S.A. 94 (1997): 13961-13966. PubMed: 9391135.
2. Crowe, J. E., Jr., et al. "Live Subgroup B Respiratory Syncytial Virus Vaccines That Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates." J. Infect. Dis. 173 (1996): 829-839. PubMed: 8603960.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898